Hemopexin is up-regulated in plasma from type 1 diabetes mellitus patients: Role of glucose-induced ROS

Journal of Proteomics

Volumn 75, Issue 12, 2012, Pages 3760-3777

  Chen, Chia Ching ^a   Lu, Ying Chieh ^b   Chen, Yi Wen ^b   Lee, Wen Li ^a   Lu, Chieh Hsiang ^c   Chen, You Hsuan ^b   Lee, Yun Ching ^b   Lin, Szu Ting ^b   Timms, John F ^d   Lee, Ying Ray ^c,e   Chou, Hsiu Chuan ^b   Chan, Hong Lin ^b  

^a CHIA YI CHRISTIAN HOSPITAL   (Taiwan)

^b NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^c Chiayi Chirsitan Hospital   (Taiwan)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e MIN HWEI COLLEGE OF HEALTH CARE MANAGEMENT   (Taiwan)

Author keywords

2D DIGE; Hemopexin; MALDI TOF mass spectrometry; Reactive oxygen species; Type 1 diabetes mellitus

Indexed keywords

CYSTEINE; GLUCOSE; GLUTATHIONE; HEMOPEXIN; LYSINE; REACTIVE OXYGEN METABOLITE; THIOL;

ARTICLE; CONTROLLED STUDY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEPLETION; PROTEIN EXPRESSION; STRUCTURAL PROTEOMICS; TWO DIMENSIONAL GEL ELECTROPHORESIS; UPREGULATION;

ADOLESCENT; BIOLOGICAL MARKERS; BLOOD PROTEINS; CELLS, CULTURED; CHILD; DIABETES MELLITUS, TYPE 1; GLUCOSE; HEMOPEXIN; HUMANS; REACTIVE OXYGEN SPECIES; UP-REGULATION;

EID: 84862177243     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2012.04.047     Document Type: Article

References (54)

1. Finne P., Reunanen A., Stenman S., Groop P.H., Gronhagen-Riska C. Incidence of end-stage renal disease in patients with type 1 diabetes. JAMA 2005, 294:1782-1787.
2. Cameron J.S. The discovery of diabetic nephropathy: from small print to centre stage. J Nephrol 2006, 19(Suppl. 10):S75-S87.
3. Merchant M.L., Klein J.B. Proteomic discovery of diabetic nephropathy biomarkers. Adv Chronic Kidney Dis 2010, 17:480-486.
4. D'Hertog W., Mathieu C., Overbergh L. Type 1 diabetes: entering the proteomic era. Expert Rev Proteomics 2006, 3:223-236.
5. Bang-Berthelsen C.H., Pedersen L., Floyel T., Hagedorn P.H., Gylvin T., Pociot F. Independent component and pathway-based analysis of miRNA-regulated gene expression in a model of type 1 diabetes. BMC Genomics 2011, 12:97.
6. Reynier F., Pachot A., Paye M., Xu Q., Turrel-Davin F., Petit F., et al. Specific gene expression signature associated with development of autoimmune type-I diabetes using whole-blood microarray analysis. Genes Immun 2010, 11:269-278.
7. Giacco F., Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010, 107:1058-1070.
8. Vlassara H., Palace M.R. Glycoxidation: the menace of diabetes and aging. Mt Sinai J Med 2003, 70:232-241.
9. Nishikawa T., Edelstein D., Du X.L., Yamagishi S., Matsumura T., Kaneda Y., et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000, 404:787-790.
10. Cumming R.C., Andon N.L., Haynes P.A., Park M., Fischer W.H., Schubert D. Protein disulfide bond formation in the cytoplasm during oxidative stress. J Biol Chem 2004, 279:21749-21758.
11. Timms J.F., Cramer R. Difference gel electrophoresis. Proteomics 2008, 8:4886-4897.
12. Huang H.L., Hsing H.W., Lai T.C., Chen Y.W., Lee T.R., Chan H.T., et al. Trypsin-induced proteome alteration during cell subculture in mammalian cells. J Biomed Sci 2010, 17:36.
13. Lin C.P., Chen Y.W., Liu W.H., Chou H.C., Chang Y.P., Lin S.T., et al. Proteomic identification of plasma biomarkers in uterine leiomyoma. Mol Biosyst 2012, 8:1136-1145.
14. Chen Y.W., Liu J.Y., Lin S.T., Li J.M., Huang S.H., Chen J.Y., et al. Proteomics analysis of gemcitabine-induced drug resistance in pancreatic cancer cells. Mol Biosyst 2011, 7:3065-3074.
15. Chen Y.W., Chou H.C., Lyu P.C., Yin H.S., Huang F.L., Chang W.S., et al. Mitochondrial proteomics analysis of tumorigenic and metastatic breast cancer markers. Funct Integr Genomics 2011, 11:225-229.
16. Chou H.C., Chen Y.W., Lee T.R., Wu F.S., Chan H.T., Lyu P.C., et al. Proteomics study of oxidative stress and Src kinase inhibition in H9C2 cardiomyocytes: a cell model of heart ischemia reperfusion injury and treatment. Free Radic Biol Med 2010, 49:96-108.
17. Gharbi S., Gaffney P., Yang A., Zvelebil M.J., Cramer R., Waterfield M.D., et al. Evaluation of two-dimensional differential gel electrophoresis for proteomic expression analysis of a model breast cancer cell system. Mol Cell Proteomics 2002, 1:91-98.
18. Hung P.H., Chen Y.W., Cheng K.C., Chou H.C., Lyu P.C., Lu Y.C., et al. Plasma proteomic analysis of the critical limb ischemia markers in diabetic patients with hemodialysis. Mol Biosyst 2011, 7:1990-1998.
19. Chan H.L., Gaffney P.R., Waterfield M.D., Anderle H., Peter M.H., Schwarz H.P., et al. Proteomic analysis of UVC irradiation-induced damage of plasma proteins: serum amyloid P component as a major target of photolysis. FEBS Lett 2006, 580:3229-3236.
20. Chan H.L., Gharbi S., Gaffney P.R., Cramer R., Waterfield M.D., Timms J.F. Proteomic analysis of redox- and ErbB2-dependent changes in mammary luminal epithelial cells using cysteine- and lysine-labelling two-dimensional difference gel electrophoresis. Proteomics 2005, 5:2908-2926.
21. Candiloros H., Muller S., Zeghari N., Donner M., Drouin P., Ziegler O. Decreased erythrocyte membrane fluidity in poorly controlled IDDM. Influence of ketone bodies. Diabetes Care 1995, 18:549-551.
22. Saydah S.H., Miret M., Sung J., Varas C., Gause D., Brancati F.L. Postchallenge hyperglycemia and mortality in a national sample of U.S. adults. Diabetes Care 2001, 24:1397-1402.
23. Jouven X., Lemaitre R.N., Rea T.D., Sotoodehnia N., Empana J.P., Siscovick D.S. Diabetes, glucose level, and risk of sudden cardiac death. Eur Heart J 2005, 26:2142-2147.
24. Cai L., Li W., Wang G., Guo L., Jiang Y., Kang Y.J. Hyperglycemia-induced apoptosis in mouse myocardium: mitochondrial cytochrome C-mediated caspase-3 activation pathway. Diabetes 2002, 51:1938-1948.
25. Chan H.T., Lee T.R., Huang S.H., Lee H.Y., Sang T.K., Chan H.L. Proteomic analysis of a drosophila IBMPFD model reveals potential pathogenic mechanisms. Mol Biosyst 2012, 8:1730-1741.
26. Lai T.C., Chou H.C., Chen Y.W., Lee T.R., Chan H.T., Shen H.H., et al. Secretomic and proteomic analysis of potential breast cancer markers by two-dimensional differential gel electrophoresis. J Proteome Res 2010, 9:1302-1322.
27. Wu C.L., Chou H.C., Cheng C.S., Li J.M., Lin S.T., Chen Y.W., et al. Proteomic analysis of UVB-induced protein expression- and redox-dependent changes in skin fibroblasts using lysine- and cysteine-labeling two-dimensional difference gelelectrophoresis. J Proteomics 2012, 75:1991-2014.
28. Tolosano E., Altruda F. Hemopexin: structure, function, and regulation. DNA Cell Biol 2002, 21:297-306.
29. Mohanty P., Hamouda W., Garg R., Aljada A., Ghanim H., Dandona P. Glucose challenge stimulates reactive oxygen species (ROS) generation by leucocytes. J Clin Endocrinol Metab 2000, 85:2970-2973.
30. Wolff S.P., Jiang Z.Y., Hunt J.V. Protein glycation and oxidative stress in diabetes mellitus and ageing. Free Radic Biol Med 1991, 10:339-352.
31. Chou H.C., Lu Y.C., Cheng C.S., Chen Y.W., Lyu P.C., Lin C.W., et al. Proteomic and redox-proteomic analysis of berberine-induced cytotoxicity in breast cancer cells. J Proteomics 2012, 75(11):3158-3176.
32. Targher G., Chonchol M., Zoppini G., Franchini M. Hemostatic disorders in type 1 diabetes mellitus. Semin Thromb Hemost 2011, 37:58-65.
33. Rader D.J. Regulation of reverse cholesterol transport and clinical implications. Am J Cardiol 2003, 92:42J-49J.
34. Rohrer L., Hersberger M., von Eckardstein A. High density lipoproteins in the intersection of diabetes mellitus, inflammation and cardiovascular disease. Curr Opin Lipidol 2004, 15:269-278.
35. Walldius G., Jungner I. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy-a review of the evidence. J Intern Med 2006, 259:493-519.
36. Wang X.H., Chen S.F., Jin H.M., Hu R.M. Differential analyses of angiogenesis and expression of growth factors in micro- and macrovascular endothelial cells of type 2 diabetic rats. Life Sci 2009, 84:240-249.
37. Abaci A., Oguzhan A., Kahraman S., Eryol N.K., Unal S., Arinc H., et al. Effect of diabetes mellitus on formation of coronary collateral vessels. Circulation 1999, 99:2239-2242.
38. Toblli J.E., Cao G., DeRosa G., Di Gennaro F., Forcada P. Angiotensin-converting enzyme inhibition and angiogenesis in myocardium of obese Zucker rats. Am J Hypertens 2004, 17:172-180.
39. Boodhwani M., Sodha N.R., Mieno S., Xu S.H., Feng J., Ramlawi B., et al. Functional, cellular, and molecular characterization of the angiogenic response to chronic myocardial ischemia in diabetes. Circulation 2007, 116:I31-I37.
40. Hart A.W., Baeza N., Apelqvist A., Edlund H. Attenuation of FGF signalling in mouse beta-cells leads to diabetes. Nature 2000, 408:864-868.
41. Kimura H., Miyashita H., Suzuki Y., Kobayashi M., Watanabe K., Sonoda H., et al. Distinctive localization and opposed roles of vasohibin-1 and vasohibin-2 in the regulation of angiogenesis. Blood 2009, 113:4810-4818.
42. Smith A., Morgan W.T. Hemopexin-mediated heme transport to the liver. J Biol Chem 1985, 260:8325-8329.
43. Madian A.G., Myracle A.D., Diaz-Maldonado N., Rochelle N.S., Janle E.M., Regnier F.E. Differential carbonylation of proteins as a function of in vivo oxidative stress. J Proteome Res 2011, 10:3959-3972.
44. Frantikova V., Borvak J., Kluh I., Moravek L. Amino acid sequence of the N-terminal region of human hemopexin. FEBS Lett 1984, 178:213-216.
45. Gillery P. Oxidative stress and protein glycation in diabetes mellitus. Ann Biol Clin (Paris) 2006, 64:309-314.
46. Yan S.F., Ramasamy R., Schmidt A.M. Receptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory response. J Mol Med (Berl) 2009, 87:235-247.
47. Boulanger E., Wautier J.L., Dequiedt P., Schmidt A.M. Glycation, glycoxidation and diabetes mellitus. Nephrol Ther 2006, 2(Suppl. 1):S8-S16.
48. Vlassara H. The AGE-receptor in the pathogenesis of diabetic complications. Diabetes Metab Res Rev 2001, 17:436-443.
49. Zill H., Gunther R., Erbersdobler H.F., Folsch U.R., Faist V. RAGE expression and AGE-induced MAP kinase activation in Caco-2 cells. Biochem Biophys Res Commun 2001, 288:1108-1111.
50. Yang H., Jin X., Wai Kei L.C., Yan S.K. Review: oxidative stress and diabetes mellitus. Clin Chem Lab Med 2011.
51. Trougakos I.P., Gonos E.S. Regulation of clusterin/apolipoprotein J, a functional homologue to the small heat shock proteins, by oxidative stress in ageing and age-related diseases. Free Radic Res 2006, 40:1324-1334.
52. Kim J.H., Kim J.H., Jun H.O., Yu Y.S., Min B.H., Park K.H., et al. Protective effect of clusterin from oxidative stress-induced apoptosis in human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 2010, 51:561-566.
53. Kim J.H., Kim J.H., Yu Y.S., Min B.H., Kim K.W. Protective effect of clusterin on blood-retinal barrier breakdown in diabetic retinopathy. Invest Ophthalmol Vis Sci 2010, 51:1659-1665.
54. Kim J.H., Yu Y.S., Kim J.H., Kim K.W., Min B.H. The role of clusterin in in vitro ischemia of human retinal endothelial cells. Curr Eye Res 2007, 32:693-698.